DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
This Quarter Return
-9.81%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$1.55B
AUM Growth
+$1.55B
(+14%)
Cap. Flow
+$361M
Cap. Flow
% of AUM
23.32%
Top 10 Holdings %
Top 10 Hldgs %
50.82%
Holding
63
New
11
Increased
28
Reduced
8
Closed
11
Top Buys
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$75.7M |
| 2 |
Fate Therapeutics
FATE
|
$61.3M |
| 3 |
NovoCure
NVCR
|
$37.3M |
| 4 |
AGEN
Agenus
AGEN
|
$34.4M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
$33.2M |
Top Sells
| 1 |
Avidity Biosciences
RNA
|
$23.8M |
| 2 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$17.1M |
| 3 |
Protagonist Therapeutics
PTGX
|
$14.4M |
| 4 |
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
|
$13.2M |
| 5 |
Atara Biotherapeutics
ATRA
|
$11.8M |
Sector Composition
| 1 | Healthcare | 99.98% |
| 2 | Real Estate | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
NovoCure
NVCR
$1.38B
| $82.9M | 5.31% |
1,000,000
+450,000
| +82% | +$37.3M |
|
|
BCYC
2
Bicycle Therapeutics
BCYC
$511M
| $81.4M | 5.22% |
1,855,993
+755,993
| +69% | +$33.2M |
|
3
Travere Therapeutics
TVTX
$1.56B
| $80.8M | 5.18% |
3,134,503
+684,503
| +28% | +$17.6M |
|
4
Jazz Pharmaceuticals
JAZZ
$7.75B
| $80.5M | 5.16% |
517,051
+17,051
| +3% | +$2.65M |
|
|
GBT
5
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $79.8M | 5.12% |
2,304,683
+304,683
| +15% | +$10.6M |
|
|
6
Fate Therapeutics
FATE
$120M
| $77.5M | 4.97% |
2,000,000
+1,581,963
| +378% | +$61.3M |
|
7
Madrigal Pharmaceuticals
MDGL
$9.76B
| $77.1M | 4.95% |
786,000
+286,000
| +57% | +$28.1M |
|
|
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $75.7M | 4.86% |
4,500,000
+500,000
| +13% | +$8.42M |
|
|
9
Alnylam Pharmaceuticals
ALNY
$58.5B
| $75.7M | 4.86% |
+463,663
| New | +$75.7M |
|
10
Keros Therapeutics
KROS
$618M
| $75.1M | 4.81% |
1,380,306
+80,306
| +6% | +$4.37M |
|
11
Kura Oncology
KURA
$686M
| $54.9M | 3.52% |
3,412,000
+862,000
| +34% | +$13.9M |
|
|
KDNY
12
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $49.1M | 3.15% |
3,000,000
+579,498
| +24% | +$9.48M |
|
13
Beam Therapeutics
BEAM
$1.66B
| $43.8M | 2.81% |
763,750
+63,750
| +9% | +$3.65M |
|
14
Immunovant
IMVT
$2.56B
| $39.8M | 2.55% |
7,224,613
+2,449,613
| +51% | +$13.5M |
|
15
Repare Therapeutics
RPTX
$71.7M
| $37.9M | 2.43% |
2,664,017
+564,017
| +27% | +$8.03M |
|
16
4D Molecular Therapeutics
FDMT
$288M
| $37M | 2.37% |
2,448,200
+548,200
| +29% | +$8.29M |
|
|
AGEN
17
Agenus
AGEN
$133M
| $34.4M | 2.21% |
+13,998,491
| New | +$34.4M |
|
18
Crinetics Pharmaceuticals
CRNX
$2.92B
| $33.8M | 2.17% |
1,541,715
-358,285
| -19% | -$7.86M |
|
19
Dyne Therapeutics
DYN
$1.92B
| $33.7M | 2.16% |
3,500,000
+1,207,750
| +53% | +$11.6M |
|
|
JNCE
20
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $28.9M | 1.85% |
4,259,653
+259,653
| +6% | +$1.76M |
|
21
Esperion Therapeutics
ESPR
$448M
| $27.8M | 1.79% |
6,000,000
+358,332
| +6% | +$1.66M |
|
22
KalVista Pharmaceuticals
KALV
$678M
| $25.5M | 1.64% |
1,729,757
+229,757
| +15% | +$3.39M |
|
23
Nkarta
NKTX
$151M
| $24.1M | 1.54% |
2,113,795
+849,369
| +67% | +$9.67M |
|
|
DICE
24
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $23.9M | 1.53% |
1,250,000
-91,004
| -7% | -$1.74M |
|
|
SAGE
25
DELISTED
Sage Therapeutics
SAGE
| $22.3M | 1.43% |
675,000
+175,000
| +35% | +$5.79M |
|